ISPE Belgium Affiliate

Shaping a sustainable future

With table top exhibitions and GSK site visits

When **Wednesday 27 November 2024**

Location GSK - Wavre

A visit of GSK in Wavre will be organised in the afternoon

Table tops will be accessible during the seminar

Shaping a sustainable future

08:00 – 08:45	Registration and coffee
08:45 - 09:00	Welcome *(Wim Steenackers, President ISPE Belgium Affiliate)*
09:00 - 09:15	Introduction GSK *(Emmanuel Amory, Managing Director GSK Belgium)*
09:15 - 09:30	Introduction to the new ISPE Sustainability CoP *(Ester Lovsin Barle, ISPE Global)*
09:30 - 10:00	Advancing Safe and Sustainable by Design Practices in Pharmaceutical Manufacturing *(Sarah Costers, CESPE)*
10:00 - 10:30	An introduction to the proposal for a Universal restriction on PFAS under REACH *(Maria Chiara Detragiache, CEFIC)*
10:30-10:45	**Coffee break with table top & networking**
10:45 - 11:25	Operational Decarbonization of the World's Largest Vaccine Production Facility *(Pieter-Jan Deschamps, GSK)*
11:25 - 12:00	Net-zero carbon journey: how to decarbonize a pharmaceutical production site *(Simon Gilleman, Takeda)*
12:00-13:30	**Lunch with table top & networking opportunities**
13:30 - 14:05	Circularity as a means to reach sustainability *(Karl Vrancken, Indaver)*
14:05 - 14:40	Sustainability in Aseptic Manufacturing *(David Vertongen, Pfizer)*
14:40 - 15:00	GSK Visit introduction
15:00 - 17:30	GSK Visits and parallel EL workshops: "Join the Emerging Leaders for an interactive workshop where young professionals will use MIT's En-ROADS software to model scenarios aimed at keeping global temperature rise below 2°C. Expect a dynamic panel discussion between emerging and experienced professionals, along with active audience participation, as we explore impactful climate solutions."

Bulk (W49)
Manufacturing Unit Pertussis

Bulk (W26 & W17)
Manufacturing Unit HAV-PVP

Visual Inspection & Packaging

17:30 – 18:30	Closing of the day with networking reception

ISPE® Belgium Affiliate

Shaping a sustainable future

Abstracts

PharmEco project Advancing Safe and Sustainable by Design Practices in Pharmaceutical Manufacturing and co-funded under the Innovative Health Initiative IHI.
Sarah Costers, CESPE

PHARMECO is a public-private partnership co-funded by industry and the European Union under the Innovative Health Initiative (IHI). The project aims to equip the pharmaceutical manufacturing industry with a comprehensive system for designing, operating, and evaluating the sustainability of healthcare product manufacturing throughout its lifecycle. Key objectives include enhancing early-stage pharmaceutical development with sustainable processes, scaling up and implementing environmentally friendly technologies in manufacturing practices, and establishing standardized guidelines for assessing the environmental sustainability of pharmaceuticals and biopharmaceuticals. Achieving these goals requires collaboration across multiple disciplines and involves 31 international partners, including universities, research institutes, governmental bodies, SMEs, and major pharmaceutical and medtech companies.

An introduction to the proposal for a Universal restriction on PFAS under REACH.
Maria Chiara Detragiache, CEFIC

In January 2023, the Competent Authorities from five European States submitted a proposal to the European Chemicals Agency (ECHA) for a restriction on Per- and polyfluoroalkyl substances (or PFAS) under REACH. The proposal aims at banning all uses of PFAS, unless explicitly derogated. Between March and September 2023, stakeholders, including industry, had the opportunity to submit comments on the proposal for the authorities' consideration. During the presentation, we will give an overview of the draft restriction currently under consideration, will outline next steps in the process and will report on a Cefic study looking into the uses of PFAS in industrial settings".

Shaping a sustainable future

Abstracts

Operational Decarbonization of the World's Largest Vaccine Production Facility.
Pieter-Jan Deschamps, GSK Belgium

In the quest for a healthier planet, our pharmaceutical production facility is embarking on a transformative journey towards decarbonization. Energy transition represents not just a shift, but a fundamental transformation in how we generate and utilize energy within our industry. This change is achievable only if we prioritize efficiency and focus on reducing our overall energy demand first.
During this presentation, we will give an overview of the roadmap to achieve our carbon emissions targets, we will outline next steps in the process and share some challenges, such as available technology, quality restrictions and capabilities.

Net-zero carbon journey: how to decarbonize a pharmaceutical production site.
Simon Gilleman, Takeda

Presentation will cover:
* Intro Takeda
* Sustainability (reduce / produce / innovate)
* Mapp your site energy flows
* Examples of key projects for each pillar (reduce / produce / innovate)

Circularity as a means to reach sustainability.
Karl Vrancken, Indaver

Waste management has been a point of attention for many years, both in companies and in wider society. This resulted in quantitative targets to reduce the tonnes of waste, set up separate collection and develop recycling routes. In many cases the low hanging fruit has been harvested and it gets more difficult to push the waste curve down. We need a shift in concept and shift our view towards materials management rather than waste management. How can we make processes and products more effective in their use of materials? Material flows need to be closed but also slowed and narrowed. The role of the waste manager shifts to become a material manager, with closer involvement in the product value chain. As such, circular material management becomes a tool to reach corporate sustainability goals.

In this talk we will present specific company cases and discuss how sustainability gets integrated into your waste and material management.

Shaping a sustainable future

Abstracts

Sustainability in Aseptic Manufacturing.
David Vertongen, Pfizer

This presentation balances the opportunities and challenges of sustainability in an aseptic manufacturing environment.
From maximizing the use of renewable energy, ensuring efficient usage and promote electrification to finding the balance between innovation and regulation, manage discontinuous operations in a continuous environment, all based on data-driven control and decision-making.

Shaping a sustainable future
GSK Site tours

Welcome to Bulk (W49)

The Manufacturing Unit Pertussis in Wavre produces in large quantities high-quality antigens, which are essential components of Infanrix and Boostrix Vaccines.

Specifically, in buildings W49, we manufacture antigens targeting Bordetella Pertussis. You will have a view on the fermentation process, the first manufacturing steps.

Bulk is a critical stage in the manufacturing process. It forms the basis from which the final product is developed and must meet strict specifications for purity, concentration and quality.

Shaping a sustainable future
GSK Site Tours

Welcome to Bulk (W26 & W17)

The Manufacturing Unit HAV-PVP in Wavre produces in large quantities high-quality antigens, which are essential components of vaccines.

Specifically, in buildings W17 and W26, we manufacture antigens targeting shingles, cervical cancer, Respiratory Syncytial Virus (RSV) and hepatitis A.

Bulk is a critical stage in the manufacturing process. It forms the basis from which the final product is developed and must meet strict specifications for purity, concentration and quality.

Duration of the visit : 30 min (gallery visit)
Person of contact : Marie-Laure de Voghel

Shaping a sustainable future
GSK Site Tours

Welcome to Visual Inspection and Packaging

The Visual Inspection manufacturing unit in Wavre ensures that only the highest quality vaccines proceed to the next stage of the production process. The vaccines are inspected manually, semi-automatically or automatically before being packaged.

The Packaging manufacturing unit in Wavre plays a crucial role in ensuring that vaccines are properly packaged, labeled, and ready to be distributed, always adhering to the regulatory requirements.

Shaping a sustainable future

Who should attend?

All stakeholders responsible for:

- Research & Development
- Clinical trials manufacturing and scale up
- Manufacturing & Quality Control
- Technology & Engineering & Automation
- Logistics & Distribution
- Supply Chain
- Regulatory, validation, QA & GMP

and active in:

- Pharmaceuticals
- Biopharmaceuticals
- Biologics
- API
- And related Life Science industries…

Registration

- Open for ISPE Members or Non-ISPE Members
- Registration required (before 10 November) via website : www.ispeconference.org
- Including Lunch and Networking
- Including site visit
- Price :
  - 395 € (for ISPE member)
  - 95 € (for ISPE member – Emerging Leader(*age under 30*))
  - 595 € (for Non ISPE Member, including 1 year membership)
  - 295 € (for Non ISPE member – Emerging Leader (*age under 30)*, including 1 year membership)
- See registration website for payment details.

Contact : info@ispe.be

- ISPE reserves the right to delay the meeting and modify the program and the place, in case of force majeure.
- Any cancellation received later than one week before the event will not be credited.

ISPE Belgium Affiliate

Shaping a sustainable future

Event location



GSK

Shaping a sustainable future

GOLD Sponsors

SILVER Sponsors

BRONZE Sponsors

ISPE®
Belgium
Affiliate